Ownership Action to Note: Pro-Misonix Inc Institutional Investors Sentiment Runs High in 2016 Q2

November 18, 2016 - By Ruchi Gupta   ·   0 Comments

Ownership Action to Note: Pro Misonix Inc Institutional Investors Sentiment Runs High in  2016 Q2

Sentiment for Misonix Inc (NASDAQ:MSON)

Misonix Inc (NASDAQ:MSON) institutional sentiment increased to 2.5 in Q2 2016. Its up 1.87, from 0.63 in 2016Q1. The ratio is better, as 5 funds increased or started new positions, while 8 sold and reduced stock positions in Misonix Inc. The funds in our partner’s database now own: 1.06 million shares, down from 1.13 million shares in 2016Q1. Also, the number of funds holding Misonix Inc in their top 10 positions was flat from 0 to 0 for the same number . Sold All: 4 Reduced: 4 Increased: 4 New Position: 1.

MISONIX, INC. , designs, manufactures, develops and markets minimally invasive ultrasonic surgical device products. The company has a market cap of $65.43 million. These products include the BoneScalpel cutting systemwhich is used among other things for surgical procedures of the spine and on maxillofacial procedures, the SonaStar Surgical Aspirator which is used to emulsify and remove soft and hard tumors, the SonicOne Wound Cleansing and Debridement System that offers tissue specific debridement and cleansing of wounds for effective removal of devitalized tissue and fibrin deposits while sparing viable cells, and the AutoSonix ultrasound cutting and coagulating system, which is distributed and marketed for Misonix through an agreement with Covidien Ltd. It has a 24.1 P/E ratio. Misonix also markets its Lysonix soft tissue aspirator used for cosmetic surgery through Mentor Corporation, a subsidiary of Johnson & Johnson .

About 3,300 shares traded hands. Misonix, Inc. (NASDAQ:MSON) has risen 35.62% since April 18, 2016 and is uptrending. It has outperformed by 31.19% the S&P500.

According to Zacks Investment Research, “Misonix, Inc. designs, develops, manufactures, and markets medical, scientific, and industrial ultrasonic equipment, laboratory safety equipment, and air pollution control products. Misonix’s ultrasonic platform is the basis for several innovative medical technologies. Misonix has a minority equity position in Focus Surgery, Inc. which uses high intensity focused ultrasound technology to destroy deep-seated cancerous tissues without affecting surrounding healthy tissue. Misonix acquired worldwide rights to use the Focus technology in kidney, liver and breast treatment. Addressing a combined market estimated to be in excess of $four billion annually, Misonix’s proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications.”

Wealthtrust Axiom Llc holds 0.17% of its portfolio in Misonix, Inc. for 86,836 shares. Grandeur Peak Global Advisors Llc owns 52,251 shares or 0.06% of their US portfolio. Moreover, Cadence Capital Management Llc has 0.03% invested in the company for 75,550 shares. The United Kingdom-based Rathbone Brothers Plc has invested 0.01% in the stock. Blackrock Fund Advisors, a California-based fund reported 12,687 shares.#img1#

Insider Transactions: Since January 1, 0001, the stock had 2 insider buys, and 0 insider sales for $4.04 million net activity.

MSON Company Profile

MISONIX, INC. (Misonix), incorporated on July 31 1967, designs, makes, develops and markets minimally invasive ultrasonic surgical device products. These products include the BoneScalpel cutting systemwhich is used among other things for surgical procedures of the spine and on maxillofacial procedures, the SonaStar Surgical Aspirator which is used to emulsify and remove soft and hard tumors, the SonicOne Wound Cleansing and Debridement System that offers tissue specific debridement and cleansing of wounds for effective removal of devitalized tissue and fibrin deposits while sparing viable cells, and the AutoSonix ultrasound cutting and coagulating system, which is distributed and marketed for Misonix through an agreement with Covidien Ltd. Misonix also markets its Lysonix ultrasound assisted liposuction device through Mentor Corporation, a subsidiary of Johnson & Johnson . On October 19, 2011, it sold its Laboratory and Forensic Safety Products business to Mystaire, Inc.

More notable recent Misonix, Inc. (NASDAQ:MSON) news were published by: Prnewswire.com which released: “Misonix, Inc. Announces Exclusive Agreement with SonoSpine, LLC” on August 10, 2016, also Prnewswire.com with their article: “Stavros Vizirgianakis, Interim Misonix CEO, Invests $4 Million in Misonix …” published on October 25, 2016, Prnewswire.com published: “Misonix To Host BoneScalpel® Hands-on Lab at Upcoming NASS” on October 25, 2016. More interesting news about Misonix, Inc. (NASDAQ:MSON) were released by: Prnewswire.com and their article: “Harwood Feffer LLP Announces Investigation of Misonix, Inc.” published on November 01, 2016 as well as Reuters.com‘s news article titled: “BRIEF-Misonix Inc files for non timely 10-q” with publication date: November 10, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Ruchi Gupta


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>